Market Research Logo

Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review

Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review provides

- you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc Key Recent Developments

May 08,2018 Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
May 01,2018 Aerie Pharmaceuticals Names Concetta Perro As Commercial Counsel
Apr 12,2018 Aerie Pharmaceuticals Announces Appointment Of Scott Laranjo As Director, Marketing, Roclatan
Feb 28,2018 Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Aerie Pharmaceuticals Inc - Key Facts
Aerie Pharmaceuticals Inc - Key Employees
Aerie Pharmaceuticals Inc - Key Employee Biographies
Aerie Pharmaceuticals Inc - Major Products and Services
Aerie Pharmaceuticals Inc - History
Aerie Pharmaceuticals Inc - Company Statement
Aerie Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Aerie Pharmaceuticals Inc - Business Description
R&D Overview
Aerie Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Aerie Pharmaceuticals Inc - Strengths
Aerie Pharmaceuticals Inc - Weaknesses
Aerie Pharmaceuticals Inc - Opportunities
Aerie Pharmaceuticals Inc - Threats
Aerie Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aerie Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Apr 12, 2018: Aerie Pharmaceuticals Announces Appointment Of Scott Laranjo As Director, Marketing, Roclatan
Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure
Feb 12, 2018: Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
Feb 08, 2018: Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
Feb 01, 2018: Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications
Jan 16, 2018: Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
Jan 02, 2018: Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Aerie Pharmaceuticals Inc, Key Facts
Aerie Pharmaceuticals Inc, Key Employees
Aerie Pharmaceuticals Inc, Key Employee Biographies
Aerie Pharmaceuticals Inc, Major Products and Services
Aerie Pharmaceuticals Inc, History
Aerie Pharmaceuticals Inc, Other Locations
Aerie Pharmaceuticals Inc, Subsidiaries
Aerie Pharmaceuticals Inc, Key Competitors
Aerie Pharmaceuticals Inc, Ratios based on current share price
Aerie Pharmaceuticals Inc, Annual Ratios
Aerie Pharmaceuticals Inc, Annual Ratios (Cont...1)
Aerie Pharmaceuticals Inc, Interim Ratios
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aerie Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Aerie Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Aerie Pharmaceuticals Inc, Ratio Charts
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report